New EU Scrutiny Procedure Less Widely Applicable And Less Complex Than Expected
This article was originally published in Clinica
Executive Summary
One of the greatest hurdles in the future medtech Regulations – the highly demanding scrutiny procedures for high-risk devices and IVDs – now looks less widely applicable than industry had expected. Amanda Maxwell spoke with MedTech Europe’s John Brennan and Jesus Rueda to find out more
You may also be interested in...
More EU Clinical Data Requirements Coming With New Regulations
In the EU, a two-step strengthening of requirements for clinical data means manufacturers and notified bodies need to act now, well ahead of the new Medical Device Regulations taking effect. Sarah Sorrel, president of device clinical research organization Medpass International, explains how and why in this guest column.
EU Regulatory Experts Support Notified Bodies, But Argue For Greater Consistency
Notified bodies have been a pivotal part of the EU medtech regulatory system since it was first launched in the 1990s. Where might they fit within a new medtech regulatory governance structure? Panelists on a recent vodcast grappled with the question.
First Public Discussion On How EU Medtech Regulatory Governance Structure May Evolve
Does the EU need a medtech agency for the first time in its history? Nothing can or should be decided too quickly but five high-profile experts broadly agreed that change is now critical.